Is cerebrolysin FDA-approved, and what does the research show?

What is cerebrolysin?

Cerebrolysin is not a single peptide. It is a mixture of low-molecular-weight peptides and amino acids derived from pig brain ¹. Reviewers describe it as "said to have neurotrophic and neuroprotective activity," that is, to support the growth and survival of nerve cells ⁵. It is given as a series of daily intravenous infusions ⁵.

It is widely used for acute ischemic stroke in Russia, Eastern Europe, China and other Asian and post-Soviet countries ¹. A 2021 review says it is used clinically in more than 50 countries ¹⁰. The name is a brand. The product is made by EVER Pharma, an Austrian company, as a prescription solution for injection ².

Is cerebrolysin FDA-approved?

No. Cerebrolysin is not FDA-approved: Drugs@FDA lists no approved cerebrolysin product as of November 9, 2026 ³. It is a prescription injection from an Austrian maker ². A 2021 review of its clinical use says it is used in more than 50 countries but "not approved for use in the USA" ¹⁰.

It is also absent from FDA's list of bulk drug substances nominated for compounding under section 503A, updated May 14, 2026, in all three of its categories ⁴. Section 503A is the part of federal law that covers pharmacies compounding a medicine to a clinician's prescription. FDA's records therefore show no approved product and no listed compounding nomination for cerebrolysin as of November 9, 2026 ⁴, ³. The manufacturer lists it as a prescription medicine for dementia of Alzheimer's type, vascular dementia, stroke and traumatic brain injury ². A product's approval in another country is not an FDA approval.

See the FDA status of every peptide, updated weekly.

How does cerebrolysin work?

The mechanism is proposed, not proven in people. A 2021 review describes cerebrolysin as stimulating molecular signaling pathways involved in "neurological regeneration and support" ¹⁰. Most of the mechanism evidence comes from animals.

Studied in mice bred to develop Alzheimer's-type changes, cerebrolysin increased the number of new nerve-cell precursors in the hippocampus, a brain region involved in memory, and reduced their death ⁸. Studied in mice given a nerve toxin, four weeks of pretreatment protected nerve structure and maze performance, while treatment given after the toxin did not ⁹. Studied in rats with a crushed optic nerve, injections into the abdominal cavity, a systemic route, preserved retinal cells and visual signals ⁷. Injection directly into the nerve was harmful ⁷.

What does the research show?

Stroke. Studied in people: a 2023 Cochrane review included seven randomized trials with 1,773 participants, one of them a trial of Cortexin, a similar peptide mixture ¹. Treatment began within 48 hours of an acute ischemic stroke and was compared with placebo or no treatment ¹. Across six trials with 1,689 participants, "Cerebrolysin or Cortexin probably result in little to no difference in all-cause death," which the authors rate moderate-certainty evidence ¹. None of the trials reported poor functional outcome, meaning death or dependence at the end of follow-up, or quality of life ¹. The manufacturer supported three of the multicenter trials ¹.

Vascular dementia. Studied in people: a 2019 Cochrane review found six randomized trials with 597 participants living with vascular dementia, followed for 15 days to three years ⁵. Where severity was reported, it was mild to moderate ⁵. On combined cognitive scores from three trials with 420 people, cerebrolysin scored higher than control by a standardized mean difference of 0.36 ⁵. On global function in two trials with 379 participants, responders were about 2.7 times as common with cerebrolysin ⁵.

The authors rated both findings "very low-quality evidence" and noted that every trial with funding details was industry-supported ⁵. They warned that "if there are benefits of Cerebrolysin, the effects may be too small to be clinically meaningful" ⁵. No new trial in vascular dementia had appeared since 2013 ⁵.

Dementia of any cause. Studied in people: a 2021 systematic review and meta-analysis of animal-derived nootropics pooled eight cerebrolysin trials with 793 participants for cognition ⁶. It found a small short-term gain in cognition, better global function in four trials with 479 participants, and no difference in serious adverse events ⁶. The authors judged the certainty of evidence low to very low and the effects "modest and probably less than would be considered clinically relevant" ⁶.

A 2021 literature review covering stroke, neurodegeneration and traumatic brain injury reports "inconsistent results," with several clinical studies finding minor clinical relevance and no significant advantage over placebo ¹⁰. It calls for "more robust clinical data" before the drug's role can be defined ¹⁰.

None of these reviews covers healthy people taking cerebrolysin for memory or focus; the trials they pool are all in patients with stroke or dementia ¹, ⁵, ⁶. ClinicalTrials.gov lists 43 registered studies with cerebrolysin as an intervention, 38 of them trials, as of November 9, 2026, and none lists a study site in the United States ¹¹.

What are the side effects?

The stroke trials give the clearest safety picture. In four trials with 1,607 participants, the total number of people with any adverse event was about the same with cerebrolysin or Cortexin as without, low-certainty evidence ¹. In three trials with 1,335 participants, serious adverse events overall were probably no more common with cerebrolysin ¹.

Non-fatal serious adverse events, though, were more than twice as common (risk ratio 2.39, 95% confidence interval 1.10 to 5.23), moderate-certainty evidence ¹. That increase was more marked in the two trials that gave the lower-dose, 10-day course ¹. Deaths were probably no different between groups ¹.

In vascular dementia, two trials with 379 people reported no difference in adverse effects, very low-quality evidence, and the one trial that reported deaths recorded none ⁵. Across dementia trials pooled in 2021, serious adverse events were no more common with cerebrolysin in six trials with 1,014 participants ⁶. In the clinical setting, the 2021 literature review calls it "generally safe for human use" as an adjunct treatment ¹⁰.

In sport

Cerebrolysin is not named on the World Anti-Doping Agency's (WADA) 2026 Prohibited List ¹². Under M2.2 the list prohibits "intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period" outside hospital treatment, surgery or clinical diagnostic investigations ¹². Cerebrolysin is given by intravenous infusion ⁵.

The list's S0 clause reads: "Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times" ¹². FDA, the one regulator whose records were read for this page, holds no approval for cerebrolysin ³. Its maker sells it as a prescription medicine ². The 2023 Cochrane review records that it is "listed on the national Essential Medicines Lists of Slovakia, Romania, Vietnam, Uganda, and the Syrian Arab Republic" and "recommended for use in acute ischaemic stroke by the national clinical practice guidelines of Russia" ¹. No regulator's approval record was opened for this page, so whether S0 reaches cerebrolysin is for counsel to say.

What JumpstartMD offers

JumpstartMD does not prescribe cerebrolysin. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 9, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.